Wednesday, May 04, 2011
Tuesday, May 03, 2011
Trial Drugs Can Be A Cancer Cure For Some Patients
August 2010
(credit: CBS)
AURORA, Colo. (CBS4) ― University of Colorado Cancer Center is welcoming a new director who wants to reinvent cancer research in Colorado. Dr. Dan Theodorescu is championing personalized medicine and cutting edge clinical trials to impact cancer care. That kind of approach to cancer is already making a big difference in patient lives.Tommy Stewart has been going to the University of Colorado Cancer Center, UCCC, for treatment of thyroid cancer. He’d been through several surgeries and conventional treatments, but the cancer kept coming back.
“This is approximately an inch wide tumor which is a lymph node relapse which is rather frequent in thyroid cancer,” said Dr. Antonio Jimeno, a head and neck cancer specialist at the University of Colorado Cancer Center.
“It was sort of a numb feeling…’What do we do now?’…’What’s the next step?’…’How are we going to deal with this?’,” Stewart told CBS4.
The next step was a Phase 1 clinical trial, taking an experimental drug.
“Clinical trials at all levels are critically important in pushing the ball forward and making progress in cancer,” said Dr. Dan Theodorescu, the new director at UCCC.
The experimental drug that Stewart took made big progress on his tumor. It reduced it to undetectable levels, and in Stewart’s case there were no side effects. An unusual result even in clinical trials.
“Being able to not just control but literally wipe out a thyroid cancer that is metastatic is basically…it’s very rare,” said Jimeno.
“I was totally surprised,” Steward added.
“We, at the University of Colorado Cancer Center are innovators at Phase 1 clinical trials. In fact we have one of the best Phase 1 groups in the country,” Theodorescu explained.
- Written for the Web by CBS4 Special Projects Producer Libby Smith
Monday, May 02, 2011
Two LI teens use fashion to fight pancreatic cancer
Sophie Koppelman Fritz of Roslyn Harbor and Becky Broxmeyer of Muttontown, with the help of volunteer fashion troops, have organized what promises to be a fashion extravaganza called “Fashion 4 the Cure,” at the Engineer’s Club in Roslyn Harbor, on April 6.
Read more at: http://www.newsday.com/lifestyle/fashion-and-shopping/shop-talk-1.811931/two-li-teens-use-fashion-to-fight-pancreatic-cancer-1.2789177?showAll=true
Sunday, May 01, 2011
May 2011 -- Lustgarten Events
Sunday, May 01, 2011
Tuesday, May 03, 2011
Friday, May 06, 2011
Saturday, May 14, 2011
Sunday, May 15, 2011
Monday, May 16, 2011
in Memory of Maureen Feery Doyle
2:00 PM (America/New_York)
AMF Garden City Lanes 987 Stewart Avenue Garden City, NY 11530
2:00 PM (America/New_York)
AMF Garden City Lanes 987 Stewart Avenue Garden City, NY 11530
Tuesday, May 03, 2011
Friday, May 06, 2011
Rock the Purple - Live Bands and Raffles
5:00 PM
Bogies Ale House 303 E. Kensington Mt. Prospect, IL 60056
5:00 PM
Bogies Ale House 303 E. Kensington Mt. Prospect, IL 60056
Saturday, May 14, 2011
Gold Award Cancer Awareness Run 
8:00 AM (America/New_York)
Brook Avenue School 45 Brook Avenue Bay Shore, NY 11706
8:00 AM (America/New_York)
Brook Avenue School 45 Brook Avenue Bay Shore, NY 11706
Pancreatic Cancer Research Walk - Charlotte
8:00 AM
Frank Liske Park 4001 Stough Road Concord, NC 2802
8:00 AM
Frank Liske Park 4001 Stough Road Concord, NC 2802
Sunday, May 15, 2011
Pancreatic Cancer Research Walk - Brooklyn
8:00 AM (America/New_York)
Marine Park Stuart Street and Avenue S Brooklyn, NY 11229
8:00 AM (America/New_York)
Marine Park Stuart Street and Avenue S Brooklyn, NY 11229
Pancreatic Cancer Research Walk - Monmouth
12:00 PM (America/New_York)
Monmouth University 400 Cedar Avenue West Long Branch, NJ 07764
12:00 PM (America/New_York)
Monmouth University 400 Cedar Avenue West Long Branch, NJ 07764
Monday, May 16, 2011
Bill Tamburro, Jr. Memorial Golf Tournament
7:30 AM
Lyman Orchards Golf Club 70 Lyman Road Middlefield, CT 06455
7:30 AM
Lyman Orchards Golf Club 70 Lyman Road Middlefield, CT 06455
Candi Alma Memorial Golf Outing
10:00 AM (America/New_York)
Hamlet Golf and Country Club 1 Clubhouse Drive Commack, NY 11725
10:00 AM (America/New_York)
Hamlet Golf and Country Club 1 Clubhouse Drive Commack, NY 11725
Friday, April 29, 2011
Lustgarten Research Update Corner: Spring 2011
The Lustgarten Foundation helped support Dr. Bert Vogelstein, The Johns Hopkins Kimmel Cancer Center, and his team to sequence the genome of pancreatic cancers. At the time of its completion in 2008, the pancreatic cancer genome project* represented the most complete genetic analysis of any tumor type. The project has laid the groundwork for new areas of pancreatic cancer investigation, serving as a steppingstone for additional studies in promising new directions. In this issue of Research Update Corner, we will focus on three exciting new studies that are shaping the way researchers look at the development, diagnosis and detection of the disease. The studies build on insights gained from the landmark pancreatic cancer genome project.
In October 2010, news broke in the prestigious journal Nature by Dr. Shinichi Yachida and colleagues in the laboratory of Dr. Christine Iacobuzio-Donahue of Johns Hopkins University describing that pancreatic cancer develops much more slowly than scientists thought.This discovery contradicts an existing idea that pancreatic cancers spread early in their development. Rather, Dr. Iacobuzio and colleagues found that it takes at least a decade from the first cancer-causing mutation in a normal pancreas cell, until the development of a full-blown cancer cell. It takes another five to seven years before this initial cancer cell turns into a tumor, detectable through traditional imaging methods. In other words, pancreatic cancer takes more than a decade to develop, and up to another seven years to spread. This pivotal discovery offers critical insights to researchers, defining a window of opportunity in which to detect pancreatic cancer early, when the chances for a cure are greatest.
Nevertheless, to take advantage of this exciting information, scientists need powerful research tools that can detect early mutations in pancreas cells. In addition, they need to better understand the processes that cause normal cells to start down the long road to going “bad.” Dr. Qing Wang and colleagues in the laboratory of Dr. Vogelstein recently reported in the journal Proceedings of the National Academy of Sciences (PNAS) that changes in DNA (mutations) can be detected in proteins. We know from the pancreatic cancer genome project that nearly all pancreatic cancers have a K-ras gene DNA mutation, making this gene an ideal target for early detection.Dr. Vogelstein used the cutting edge SRM technology to see these mutations in proteins. A previous installment of RUC explained how pancreatic cancer is currently understood and treated based on what we see about it, and how biomarkers can be used to detect the presence of cancer before it is visible under a microscope and through current imaging technologies. Although Dr. Vogelstein’snovel use of SRM technology is not ready for use in the clinic, it holds exciting potential for using protein biomarkers in the early detection of pancreatic cancer. Today, with support from The Lustgarten Foundation, Dr. Vogelstein and his team are actively working to optimize SRM technology for use in blood and cystic fluids.
Another exciting study published inScience by Dr. David Ting and colleagues in the laboratory of Dr. Daniel Haber of Massachusetts General Hospital (MGH) Cancer Center has revealed a previously unknown role of small snipets of DNA known as “satellite repeats.” You may know that human DNA contains genes, but what is less known is that only approximately 2% of our DNA codes for genes; the rest is unknown—a “big black box” of the human genome.
Until now, satellite repeats have been thought to be a largely inactive part of the genome, a sort of “junk” in the black box. Drs. Ting and Haber studied pancreatic cancer, and discovered that satellite repeats become active as the disease develops. In fact, satellite repeats become progressively more active as pancreatic cancer moves from early to later stages. Further, they are not active in normal tissue. The findings may offer a novel cancer biomarker for pancreatic cancer, and together, these three studies and hold exciting promise for early detection of the disease.
Now in phase 2, The Lustgarten Foundation’s Biomarker Development Project will validate the antibodies deemed predictive of early pancreatic cancer lesions. This large-scale validation phase will be conducted by PCRC member institution Dana-Farber Cancer Institute/Harvard Medical School, in cooperation with University of California at San Francisco and Fred Hutchinson Cancer Research Center.
*The pancreatic cancer genome project was made possible with major funding The Sol Golman Charitable Trust and The Lillian Goldman Charitable Trust, and significant funding from The Lustgarten Foundation.
Wednesday, April 27, 2011
UCSF Scientists Discover Link Between Inflammation and Pancreatic Cancer
Source: Jason Bardi
Solving part of a medical mystery, researchers at the University of California, San Francisco (UCSF) have established a link between molecules found in an inflamed pancreas and the early formation of pancreatic cancer – a discovery that may help scientists identify new ways to detect, monitor and treat this deadly disease.
Scientists have known for many years that pancreatitis, a painfully inflamed pancreas, is a common risk factor for pancreatic cancer – along with things like smoking and diet. But nobody knew exactly why.
Now the UCSF team, led by Matthias Hebrok, PhD, has discovered at least part of the connection. In an article appearing in the journal Cancer Cell this week, they show that two molecular “signals” produced abundantly in the pancreas during inflammation – a protein named Stat3 – helps initiate the early stages of pancreatic cancer, while another protein, called MMP7, appears to affect metastasis.
In laboratory experiments, Hebrok and his colleagues showed that blocking these proteins in mice shrunk the number of lesions that can lead to cancer and reduced the extent of cancer metastasis. They also showed that one of these molecules, MMP7, may be a clinical indicator of cancer stage, possibly making it useful as a marker for more aggressive disease. The research could also help identify new ways to target pancreatic cancer with drugs.
“If you are able to down-regulate inflammatory signals at an early stage of the disease, you may be able to curb the formation of early lesions,” said Hebrok, who directs the UCSF Diabetes Center and is the Hurlbut-Johnson Distinguished Professor in Diabetes Research.
One of the problems with the disease is that there are no reliable, sensitive screens that allow doctors to catch it early. By the time it is detected, the cancer often is so advanced it cannot be surgically removed or easily treated.
Like many scientists who study diabetes, Hebrok is very familiar with pancreatic cancer, because diabetes onset often precedes the cancer diagnosis and may be one of the warning signs. Part of his research in the past few years has involved looking at the microscopic changes that take place in the pancreatic organ when cancer emerges.
The pancreas is a 6-inch-long gland sandwiched between the stomach and the backbone. Inside are tiny cavities called “acini” in which enzymes are produced that drain through ducts into the stomach to help digest food. Pancreatic cancer may start in these cavities or in the ducts when the cells lining them undergo transformations and begin multiplying, forming cancerous lesions – a process often kick-started by inflammation.
Hebrok and his colleagues have discovered that the molecule Stat3 is a key player in this process. It is produced in the pancreas and induces the cells of the pancreas to proliferate as part of a normal healing process in response to inflammation. Sometimes this process goes awry, however, and leads to the transformation of normal cells into cancerous ones. Stat3 also increases the amount of MMP7, which contributes to cancer metastasis.
The UCSF team showed that blocking MMP7 in mice blocks metastasis and reduces the size of cancer tumors. Collaborating with a group at the University of Utah, they examined blood samples taken from people with pancreatic cancer, and they found that those with more MMP7 in their blood were more likely to be at an advanced stage of cancer.
This suggests that MMP7 might be a useful marker to guide treatment for people with pancreatic cancer. And the new insight into the overall process of how inflammation is linked to pancreatic cancer might help scientists identify new targets for cancer therapy – if ways of interfering in the process can be found and if those approaches prove effective in clinical trials
“As with many things, timing is critical,” Hebrok said. “We will need to understand in more detail during which stage of the disease therapeutic targets are activated to efficiently inhibit their function and thus cancer formation and progression.”
Photo by Susan Merrell
http://www.ucsf.edu/news/2011/04/9694/ucsf-scientists-discover-link-between-inflammation-and-pancreatic-cancer
In laboratory experiments, Hebrok and his colleagues showed that blocking these proteins in mice shrunk the number of lesions that can lead to cancer and reduced the extent of cancer metastasis. They also showed that one of these molecules, MMP7, may be a clinical indicator of cancer stage, possibly making it useful as a marker for more aggressive disease. The research could also help identify new ways to target pancreatic cancer with drugs.
“If you are able to down-regulate inflammatory signals at an early stage of the disease, you may be able to curb the formation of early lesions,” said Hebrok, who directs the UCSF Diabetes Center and is the Hurlbut-Johnson Distinguished Professor in Diabetes Research.
Inflammation And Pancreatic Cancer
Pancreatic cancer in the United States is all too common and far too deadly. According to the National Cancer Institute, there were some 43,140 new cases of pancreatic cancer diagnosed in the United States in 2010 and 36,800 deaths from the disease last year. Overall, fewer than one in 20 people diagnosed with pancreatic cancer this year will be alive five years from now.One of the problems with the disease is that there are no reliable, sensitive screens that allow doctors to catch it early. By the time it is detected, the cancer often is so advanced it cannot be surgically removed or easily treated.
Like many scientists who study diabetes, Hebrok is very familiar with pancreatic cancer, because diabetes onset often precedes the cancer diagnosis and may be one of the warning signs. Part of his research in the past few years has involved looking at the microscopic changes that take place in the pancreatic organ when cancer emerges.
The pancreas is a 6-inch-long gland sandwiched between the stomach and the backbone. Inside are tiny cavities called “acini” in which enzymes are produced that drain through ducts into the stomach to help digest food. Pancreatic cancer may start in these cavities or in the ducts when the cells lining them undergo transformations and begin multiplying, forming cancerous lesions – a process often kick-started by inflammation.
Hebrok and his colleagues have discovered that the molecule Stat3 is a key player in this process. It is produced in the pancreas and induces the cells of the pancreas to proliferate as part of a normal healing process in response to inflammation. Sometimes this process goes awry, however, and leads to the transformation of normal cells into cancerous ones. Stat3 also increases the amount of MMP7, which contributes to cancer metastasis.
The UCSF team showed that blocking MMP7 in mice blocks metastasis and reduces the size of cancer tumors. Collaborating with a group at the University of Utah, they examined blood samples taken from people with pancreatic cancer, and they found that those with more MMP7 in their blood were more likely to be at an advanced stage of cancer.
This suggests that MMP7 might be a useful marker to guide treatment for people with pancreatic cancer. And the new insight into the overall process of how inflammation is linked to pancreatic cancer might help scientists identify new targets for cancer therapy – if ways of interfering in the process can be found and if those approaches prove effective in clinical trials
“As with many things, timing is critical,” Hebrok said. “We will need to understand in more detail during which stage of the disease therapeutic targets are activated to efficiently inhibit their function and thus cancer formation and progression.”
Photo by Susan Merrell
http://www.ucsf.edu/news/2011/04/9694/ucsf-scientists-discover-link-between-inflammation-and-pancreatic-cancer
A Great Denver Resource
Do you have a parent that would really like to stay at home but needs a little help? Home Instead Senior Care is a great resource, and their South Denver office was just honored with one of their caregivers receiving the CAREGiver of the year award. Home Instead has 65,000 caregivers around the world. We're very lucky to one of the best, right here in Denver.
Looking for in home care for a senior loved one?
You've made the right choice. Home Instead Senior Care® is the most trusted and reliable source of home care for seniors in South Denver, Cherry Creek, Cherry Hills, Centennial, Greenwood Village, Littleton, South Lakewood, Englewood, Aurora and more
Call now for a free consultation to learn more about home care options and how we can help your loved one live independently at home--where ever your loved one calls home. 303.389.5700
... or visit
http://www.facebook.com/pages/Bernina-International-AG/48494069955?ref=ts#!/pages/Home-Instead-Senior-Care-Denver-South/168074069870683
Tuesday, April 26, 2011
6th Annual Pancreatic Cancer Fundraiser in Port Jefferson, NY
Join Lustgarten at Danford's Club Aqua on April 29th to raise money for the Lustgarten Foundation for Pancreatic Cancer Research! The party starts at 5:30 pm with a buffet, open bar, raffles and dancing. Tickets are $30 and may be purchased at the door.
http://www.lustgarten.org/Page.aspx?pid=602&cid=5&ceid=326&cerid=0&cdt=4%2f29%2f2011
Monday, April 25, 2011
Upcoming Lustgarten Events
Want to support the cause? Join one of these upcoming events ... all within the next two weeks!
Tuesday, April 26, 2011
Thursday, April 28, 2011
Friday, April 29, 2011
Saturday, April 30, 2011
Friday, May 06, 2011
Tuesday, April 26, 2011
Applebee's Dining to Donate
you must present flyer to your server, please print
All Day
Applebee's 2 Executive Blvd Yonkers, NY
you must present flyer to your server, please print
All Day
Applebee's 2 Executive Blvd Yonkers, NY
Thursday, April 28, 2011
Celebrity Bartender @ Starters Riverport
7:00 PM (America/New_York)
Starters Riverport 17 W. 2nd Street Bethlehem, PA
7:00 PM (America/New_York)
Starters Riverport 17 W. 2nd Street Bethlehem, PA
Friday, April 29, 2011
6th Annual Pancreatic Cancer Fundraiser
In loving memory of Rachelle Dreznick and Steven Platzner
5:30 PM (America/New_York)
Aqua at Danfords Hotel and Marina 25 E. Broadway, Port Jefferson NY
In loving memory of Rachelle Dreznick and Steven Platzner
5:30 PM (America/New_York)
Aqua at Danfords Hotel and Marina 25 E. Broadway, Port Jefferson NY
Saturday, April 30, 2011
Pancreatic Cancer Research Walk - Delaware
Wilmington, DE
8:30 AM
Delcastle Park Delcastle Recreation Area Wilmington, DE 19801
Wilmington, DE
8:30 AM
Delcastle Park Delcastle Recreation Area Wilmington, DE 19801
Wildcat East Quogue 5K
Deadline for registration is April 20th
9:00 AM
East Quogue Elementary School 6 Central Avenue East Quogue, NY 11942
Deadline for registration is April 20th
9:00 AM
East Quogue Elementary School 6 Central Avenue East Quogue, NY 11942
2nd Annual Luau for Pancreatic Cancer Research
5:00 PM (America/New_York)
RIT Inn & Conference Center 5257 W. Henrietta Road Henrietta, NY 14467-9314
Sunday, May 01, 2011 5:00 PM (America/New_York)
RIT Inn & Conference Center 5257 W. Henrietta Road Henrietta, NY 14467-9314
2nd Annual Bowling for a Cure
in Memory of Maureen Feery Doyle
2:00 PM (America/New_York)
AMF Garden City Lanes 987 Stewart Avenue Garden City, NY 11530
Tuesday, May 03, 2011 in Memory of Maureen Feery Doyle
2:00 PM (America/New_York)
AMF Garden City Lanes 987 Stewart Avenue Garden City, NY 11530
Friday, May 06, 2011
Rock the Purple - Live Bands and Raffles
5:00 PM
Bogies Ale House 303 E. Kensington Mt. Prospect, IL 60056
5:00 PM
Bogies Ale House 303 E. Kensington Mt. Prospect, IL 60056
Welcome to BJ Walks America in the Fight Against Pancreatic Cancer
From the Lustgarten "Welcome to Community Connections" page ...
Please join me in a cause close to my heart.
As you may know, I have been deeply affected by pancreatic cancer. I lost my father, Bertram, to this dread disease when i was five years old.
As you may know, I have been deeply affected by pancreatic cancer. I lost my father, Bertram, to this dread disease when i was five years old.
Did you know that pancreatic cancer is the nation’s fourth leading cancer killer? Worse yet, unless it is found early when it can be surgically removed, there is no cure. Yet, there are no tests to find it early. How can this be?
Only ten years ago, less than a dozen researchers were focused on pancreatic cancer. There simply wasn't enough funding available to support a career in the study of this disease. As a result, pancreatic cancer was virtually ignored, and with startling consequences to patients, their families and loved ones.
I am one of those loved ones, and I decided to take a stand by walking coast to coast raising money and awareness for the Fight Against Pancreatic Cancer. I walk to honor my father and to help those battling cancer now and in the future. I created a fundraising page to support The Lustgarten Foundation. The Foundation was created to find better treatments and a cure for pancreatic cancer.
Please support me with a tax-deductible donation to The Lustgarten Foundation, and be as generous as you can. Your donation, along with my own, will help give pancreatic cancer patients a fighting chance.
Sunday, April 24, 2011
Some support for pancreatic cancer screening
NEW YORK |
NEW YORK (Reuters Health) - For people at high genetic risk of pancreas cancer, screening for the disease might be worthwhile - particularly if they're senior citizens, a new study suggests.On the other hand, the researchers say, it might not be worthwhile -- and it's too soon to make widespread recommendations on screening high-risk families.
Only about 3 of every 100 patients with pancreatic cancer have the "familial form."
But the findings in this group offer reason to be "cautiously hopeful" that there might be ways to detect the often-fatal cancer earlier, said lead researcher Dr. Emmy Ludwig, of Memorial Sloan-Kettering Cancer Center in New York.
The study, reported in the American Journal of Gastroenterology, focused on families affected by familial pancreatic cancer -- where the disease has affected two or more first-degree relatives. First-degree relatives are either parents and children, or siblings.
Pancreatic cancer, whether due to an inherited gene or not, has a dim prognosis. Only about five of every hundred patients are still alive 5 years after diagnosis. That's largely because it is rarely caught early. The symptoms include weight loss and liver problems that cause the skin to turn yellow, but those usually don't show up until the cancer has spread.
It would seem to make sense to screen people from families affected by familial pancreatic cancer, but there are still many questions. For example, researchers are not sure which tests can reliably detect pancreatic cancer in people without symptoms, which people from affected families should be screened, or at what age screening should start.
For the new study, Ludwig and her colleagues offered screening to 309 relatives of people with familial pancreatic cancer. Some had at least one first-degree relative who developed pancreatic cancer before age 50. Others had family members who developed pancreatic cancer at any age - not just a parent, child or sibling but also a grandparent, grandchild, aunt or uncle, or a sibling's child.
Some participants had gene mutations linked to hereditary pancreatic cancer, plus a family history of the disease.
Over 7 years, 109 people in the study underwent screening at least once with MRI scans of the pancreas. If the MRI showed something suspicious-looking, they could have further testing with endoscopic ultrasound, where an ultrasound probe is threaded down the throat and into the small intestine, where it is then aimed at the pancreas.
Overall, MRI scans caught potential problems in 18 study participants. Nine -- or 8 percent of the whole group - had abnormalities that could become cancer. Six later had surgery to remove these lesions, while the rest refused surgery and decided to keep up with screening.
Six of the nine patients with abnormal lesions were older than 65. Perhaps, the researchers say, this means screening after age 65 could prove most useful -- but that requires further study.
In fact, the usefulness of screening at all is still debatable. A number of groups worldwide are looking into this issue, and not all of the studies have had positive findings. In a study of 76 high-risk relatives, German researchers found that screening with endoscopic ultrasound detected a potentially pre-cancerous lesion in just one relative over 5 years.
"No single group has definitively proven that routine screening is of benefit," Ludwig told Reuters Health in an email. "Our findings, we feel, add to the growing literature that suggests screening may be worthwhile. None of us has proven it."
She said that larger, long-term studies at multiple centers are needed to figure out how, when and how often to screen relatives from affected families -- and to see whether screening actually saves lives.
"The real end point to screening is, 'Do we save lives?'" Ludwig said. And the only way to get that answer, she added, is with large multi-hospital studies that keep close track of participants for many years.
Screening apparently healthy people for a disease always has downsides. It often, for instance, leads to "false-positive" test results -- suspicious findings that later turn out to be nothing to worry about. In the meantime, however, false-positive results can lead to invasive procedures people don't really need, and unnecessary anxiety.
So studies are done to try to make sure that the benefits of screening outweigh the risks.
Right now, pancreatic cancer screening is not widely available. Furthermore, since its value isn't proven, insurance companies are unlikely to pay for it - and an average out-of-network MRI scan in the northeast U.S. costs nearly $3,000, according to information from an Aetna Inc. website.
Ludwig suggested that people from high-risk families who are interested in screening try to enroll in one of the studies being run out of several academic centers worldwide -- which, besides Sloan-Kettering, include centers in Baltimore and Seattle in the U.S., and Liverpool in the U.K.
SOURCE: bit.ly/gyZ8WQ American Journal of Gastroenterology, online April 5, 2011.
For more information: http://www.reuters.com/article/2011/04/20/us-pancreatic-cancer-screening-idUSTRE73J5K720110420
Saturday, April 23, 2011
Golden Gallop Race to Defeat Pancreatic Cancer in Colorado
The Golden Gallop: Race to Defeat Pancreatic Cancer is an annual 5K & 10K race held in Golden, Colorado.
All net proceeds from the event go to the Pancreatic Cancer Action Network, an orginization that is striving to advance research, to support patients fighting the disease, and - most importantly - to create hope.
All net proceeds from the event go to the Pancreatic Cancer Action Network, an orginization that is striving to advance research, to support patients fighting the disease, and - most importantly - to create hope.
Friday, April 22, 2011
University of Colorado: Cancer research fellow wins GI ASCO Award for pancreatic cancer research presentation
Sujatha Nallaparedy, MD, a senior fellow at the University of Colorado School of Medicine, won an award for her presentation about a pancreas cancer clinical trial at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium in January 2010.
Thursday, April 21, 2011
Wednesday, April 20, 2011
Famous People Who Suffered From Pancreatic Cancer
To see the full article, visit: http://www.associatedcontent.com/article/402933/famous_people_who_suffered_from_pancreatic_pg2.html?cat=70
Pancreatic cancer doesn't discriminate. It doesn't care whether you are tall or short, orange or blue. No one is completely immune to this deadly disease. The pancreas is a gland behind your stomach, in front of your spleen. It produces juices that help break down food and helps in the production of hormones that regulate blood sugar level.According to the National Cancer Institute pancreatic cancer is diagnosed in more than 29,000 people every year. It spreads quickly and can be difficult to treat. Even if you don't know anyone close to you that has it, every time you turn on your television you may see a movie star from the past that has battled this cancer. People that you haven't thought about in years. The famous people I am about to mention have perished from pancreatic cancer. May they rest in peace.
Michael Landon- Born Eugene Maurice Orowitz on October 31,1936 in Forest Hills, New York. Everyone knew him as Joseph "Little Joe" CartWright from the tv show Bonanza. He also was a writer, director, producer on the 70's series Little House on The Prairie and the 80's tv drama Highway To Heaven. Which he also starred in. While he was working on a pilot for a new tv show called "US" he was diagnosed with pancreatic cancer. Nearly 3 months after his diagnosis on July 1, 1991, we lost Micahel Landon. He was 54.
Joan Crawford- She was born on March 23,1905 in San Antonio, Texas. She started out acting in silent films in the 1920's and would continue acting well into the 1970's. She was one of the greatest stars to hit the movie screen for over 50 years. She starred in movies such as Mildred Pierce and Above Suspicion. She was voted the 47th Greatest Movie Star of all time by Entertainment Weekly. Pancreatic cancer took her life on May 10,1977.
Fred Gwynne- On July 10th 1926 in New York City Fred Gwynne entered this world. The son of a stockbroker. He graduated from Harvard University in 1951. His career started off the ground in 1952, which included Broadway performances. In the 1960's he landed a role on the tv show The Munsters as Herman Munster. Along side acting he also wrote and illustated children's books. On July 2,1993 at the age of 66 he died from this cancer.Donna Reed- You may remember her as the housewife on the Donna Reed Show. In 1946 she played along side Jimmy Stewart in It's a Wonderful Life. On January 14,1986 Donna Reed passed away from this disease at the age of 64. After her death the Donna Reed Foundation for the Performing Arts was organized. This non-profit organization grants scholarships for performing arts students.
According to Mayoclinic.com pancreatic cancer is seldom detected in it's early stages. Which is one of the reasons why it's a leading cause of cancer death. Symptoms of the disease may not appear until the cancer has progressed. At that point the cancer has likely spread to other organs in the body which may make surgery impossible. Researchers are understanding this disease even better than years ago. Hopefully this will lead to new treatment options.
Subscribe to:
Posts (Atom)